Beijing Huaguan Biotechnology key facts
- Developer of a pharmaceutical industrialization innovation platform intended for small molecular and ADC (Antibody-Drug-Conjugates).
- It has raised $14.3M; the latest was Later Stage VC in Feb 2026.
- Notable investors include Shun Xi Fund, SJ Jiacheng Investment Management, Lotus Lake Ventures, ZGC Science City, SB China Venture Capital — 13 tracked in total.
- Status: Privately Held (backing).
Who backs Beijing Huaguan Biotechnology
13+- ·The complete investor list: 13 names
- ·Watch Beijing Huaguan Biotechnology: the Monday email on marks, rounds and moves
Beijing Huaguan Biotechnology funding rounds
No funding rounds for Beijing Huaguan Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Beijing Huaguan Biotechnology investors
13 investors are on record for Beijing Huaguan Biotechnology, including Shun Xi Fund, SJ Jiacheng Investment Management, Lotus Lake Ventures and ZGC Science City.
About Beijing Huaguan Biotechnology
Developer of a pharmaceutical industrialization innovation platform intended for small molecular and ADC (Antibody-Drug-Conjugates). The company has a well-trained and experienced drug research and development team, and it has a variety of advanced experimental equipment to support pre-clinical pharmacy research, providing domestic and foreign pharmaceutical companies with integrated pharmaceutical R&D services.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2016
- Employees
- 200
- Website
- chempion.com.cn/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Beijing Huaguan Biotechnology doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.